Keymed Biosciences Announces 2023 Annual Results and Business Updates

Contributed by: PR Newswire

Tags

Keymed-AnnualResult2

More Like This

Keymed Biosciences Announces Interim Results for First Half of 2024

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Hansa Biopharma Interim Report January-September 2023